Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610

Min Zhang, Alex Ho, Elizabeth H. Hammond, Yoshiyuki Suzuki, R. Scott Bermudez, R. Jeffrey Lee, Michael Pilepich, William U. Shipley, Howard Sandler, Li Yan Khor, Alan Pollack, Arnab Chakravarti

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: To examine the prognostic value of nuclear and cytoplasmic survivin expression in men with locally advanced prostate cancer who were enrolled in Radiation Therapy Oncology Group (RTOG) protocol 8610. Methods and Materials: RTOG 8610 was a Phase III randomized study comparing the effect of radiotherapy plus short-term androgen deprivation with radiotherapy alone. Of the 456 eligible patients, 68 patients had suitably stained tumor material for nuclear survivin analysis and 65 patients for cytoplasmic survivin. Results: Compared with patients with nuclear survivin intensity scores of ≤191.2, those with intensity scores >191.2 had significantly improved prostate cancer survival (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.20-1.00, p = 0.0452). On multivariate analysis, nuclear survivin intensity scores >191.2 were significantly associated with improved overall survival (HR, 0.46; 95% CI, 0.25-0.86; p = 0.0156) and prostate cancer survival (HR, 0.36; 95% CI, 0.16-0.84; p = 0.0173). On univariate analysis, compared with patients with cytoplasmic survivin integrated optical density ≤82.7, those with an integrated optical density >82.7 showed a significantly increased risk of local progression (HR, 2.49; 95% CI, 1.03-6.01; p = 0.0421). Conclusion: Nuclear overexpression of survivin was associated with improved overall and prostate cancer survival on multivariate analysis, and cytoplasmic overexpression of survivin was associated with increased rate of local progression on univariate analysis in patients with locally advanced prostate cancer treated on RTOG 8610. Our results might reflect the different functions of survivin and its splice variants, which are known to exist in distinct subcellular compartments.

Original languageEnglish
Pages (from-to)1033-1042
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume73
Issue number4
DOIs
StatePublished - Mar 15 2009
Externally publishedYes

Fingerprint

Radiation Oncology
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
hazards
confidence
Confidence Intervals
intervals
Survival
optical density
progressions
Multivariate Analysis
deprivation
compartments
Androgens
tumors
Neoplasms

Keywords

  • Prognostic factor
  • Prostate cancer
  • Radiotherapy
  • Survivin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Prognostic Value of Survivin in Locally Advanced Prostate Cancer : Study Based on RTOG 8610. / Zhang, Min; Ho, Alex; Hammond, Elizabeth H.; Suzuki, Yoshiyuki; Bermudez, R. Scott; Lee, R. Jeffrey; Pilepich, Michael; Shipley, William U.; Sandler, Howard; Khor, Li Yan; Pollack, Alan; Chakravarti, Arnab.

In: International Journal of Radiation Oncology Biology Physics, Vol. 73, No. 4, 15.03.2009, p. 1033-1042.

Research output: Contribution to journalArticle

Zhang, M, Ho, A, Hammond, EH, Suzuki, Y, Bermudez, RS, Lee, RJ, Pilepich, M, Shipley, WU, Sandler, H, Khor, LY, Pollack, A & Chakravarti, A 2009, 'Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610', International Journal of Radiation Oncology Biology Physics, vol. 73, no. 4, pp. 1033-1042. https://doi.org/10.1016/j.ijrobp.2008.06.1489
Zhang, Min ; Ho, Alex ; Hammond, Elizabeth H. ; Suzuki, Yoshiyuki ; Bermudez, R. Scott ; Lee, R. Jeffrey ; Pilepich, Michael ; Shipley, William U. ; Sandler, Howard ; Khor, Li Yan ; Pollack, Alan ; Chakravarti, Arnab. / Prognostic Value of Survivin in Locally Advanced Prostate Cancer : Study Based on RTOG 8610. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 73, No. 4. pp. 1033-1042.
@article{a0c1b10640114195ab0a12c3a4a85ed9,
title = "Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610",
abstract = "Purpose: To examine the prognostic value of nuclear and cytoplasmic survivin expression in men with locally advanced prostate cancer who were enrolled in Radiation Therapy Oncology Group (RTOG) protocol 8610. Methods and Materials: RTOG 8610 was a Phase III randomized study comparing the effect of radiotherapy plus short-term androgen deprivation with radiotherapy alone. Of the 456 eligible patients, 68 patients had suitably stained tumor material for nuclear survivin analysis and 65 patients for cytoplasmic survivin. Results: Compared with patients with nuclear survivin intensity scores of ≤191.2, those with intensity scores >191.2 had significantly improved prostate cancer survival (hazard ratio [HR], 0.45; 95{\%} confidence interval [CI], 0.20-1.00, p = 0.0452). On multivariate analysis, nuclear survivin intensity scores >191.2 were significantly associated with improved overall survival (HR, 0.46; 95{\%} CI, 0.25-0.86; p = 0.0156) and prostate cancer survival (HR, 0.36; 95{\%} CI, 0.16-0.84; p = 0.0173). On univariate analysis, compared with patients with cytoplasmic survivin integrated optical density ≤82.7, those with an integrated optical density >82.7 showed a significantly increased risk of local progression (HR, 2.49; 95{\%} CI, 1.03-6.01; p = 0.0421). Conclusion: Nuclear overexpression of survivin was associated with improved overall and prostate cancer survival on multivariate analysis, and cytoplasmic overexpression of survivin was associated with increased rate of local progression on univariate analysis in patients with locally advanced prostate cancer treated on RTOG 8610. Our results might reflect the different functions of survivin and its splice variants, which are known to exist in distinct subcellular compartments.",
keywords = "Prognostic factor, Prostate cancer, Radiotherapy, Survivin",
author = "Min Zhang and Alex Ho and Hammond, {Elizabeth H.} and Yoshiyuki Suzuki and Bermudez, {R. Scott} and Lee, {R. Jeffrey} and Michael Pilepich and Shipley, {William U.} and Howard Sandler and Khor, {Li Yan} and Alan Pollack and Arnab Chakravarti",
year = "2009",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2008.06.1489",
language = "English",
volume = "73",
pages = "1033--1042",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Prognostic Value of Survivin in Locally Advanced Prostate Cancer

T2 - Study Based on RTOG 8610

AU - Zhang, Min

AU - Ho, Alex

AU - Hammond, Elizabeth H.

AU - Suzuki, Yoshiyuki

AU - Bermudez, R. Scott

AU - Lee, R. Jeffrey

AU - Pilepich, Michael

AU - Shipley, William U.

AU - Sandler, Howard

AU - Khor, Li Yan

AU - Pollack, Alan

AU - Chakravarti, Arnab

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Purpose: To examine the prognostic value of nuclear and cytoplasmic survivin expression in men with locally advanced prostate cancer who were enrolled in Radiation Therapy Oncology Group (RTOG) protocol 8610. Methods and Materials: RTOG 8610 was a Phase III randomized study comparing the effect of radiotherapy plus short-term androgen deprivation with radiotherapy alone. Of the 456 eligible patients, 68 patients had suitably stained tumor material for nuclear survivin analysis and 65 patients for cytoplasmic survivin. Results: Compared with patients with nuclear survivin intensity scores of ≤191.2, those with intensity scores >191.2 had significantly improved prostate cancer survival (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.20-1.00, p = 0.0452). On multivariate analysis, nuclear survivin intensity scores >191.2 were significantly associated with improved overall survival (HR, 0.46; 95% CI, 0.25-0.86; p = 0.0156) and prostate cancer survival (HR, 0.36; 95% CI, 0.16-0.84; p = 0.0173). On univariate analysis, compared with patients with cytoplasmic survivin integrated optical density ≤82.7, those with an integrated optical density >82.7 showed a significantly increased risk of local progression (HR, 2.49; 95% CI, 1.03-6.01; p = 0.0421). Conclusion: Nuclear overexpression of survivin was associated with improved overall and prostate cancer survival on multivariate analysis, and cytoplasmic overexpression of survivin was associated with increased rate of local progression on univariate analysis in patients with locally advanced prostate cancer treated on RTOG 8610. Our results might reflect the different functions of survivin and its splice variants, which are known to exist in distinct subcellular compartments.

AB - Purpose: To examine the prognostic value of nuclear and cytoplasmic survivin expression in men with locally advanced prostate cancer who were enrolled in Radiation Therapy Oncology Group (RTOG) protocol 8610. Methods and Materials: RTOG 8610 was a Phase III randomized study comparing the effect of radiotherapy plus short-term androgen deprivation with radiotherapy alone. Of the 456 eligible patients, 68 patients had suitably stained tumor material for nuclear survivin analysis and 65 patients for cytoplasmic survivin. Results: Compared with patients with nuclear survivin intensity scores of ≤191.2, those with intensity scores >191.2 had significantly improved prostate cancer survival (hazard ratio [HR], 0.45; 95% confidence interval [CI], 0.20-1.00, p = 0.0452). On multivariate analysis, nuclear survivin intensity scores >191.2 were significantly associated with improved overall survival (HR, 0.46; 95% CI, 0.25-0.86; p = 0.0156) and prostate cancer survival (HR, 0.36; 95% CI, 0.16-0.84; p = 0.0173). On univariate analysis, compared with patients with cytoplasmic survivin integrated optical density ≤82.7, those with an integrated optical density >82.7 showed a significantly increased risk of local progression (HR, 2.49; 95% CI, 1.03-6.01; p = 0.0421). Conclusion: Nuclear overexpression of survivin was associated with improved overall and prostate cancer survival on multivariate analysis, and cytoplasmic overexpression of survivin was associated with increased rate of local progression on univariate analysis in patients with locally advanced prostate cancer treated on RTOG 8610. Our results might reflect the different functions of survivin and its splice variants, which are known to exist in distinct subcellular compartments.

KW - Prognostic factor

KW - Prostate cancer

KW - Radiotherapy

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=61549127925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549127925&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.06.1489

DO - 10.1016/j.ijrobp.2008.06.1489

M3 - Article

C2 - 18977097

AN - SCOPUS:61549127925

VL - 73

SP - 1033

EP - 1042

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -